Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025662 · OUTCOME

Overall Survival

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS · Source last updated 2016-10-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Dec 2011.

What was measured

Percent overall survival (actuarial) at analysis in Dec 2011.

Analysis population: all patients who received the selectively depleted transplant including one special exemption

Groups in this outcome

RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants

Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants22

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants4.5Not reported013.3Not reported
Complete source fields
anticipated Posting Date
2010-07
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        13.3
        value
        4.5
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
Percent overall survival (actuarial) at analysis in Dec 2011.
dispersion Type
95% Confidence Interval
groups
  1. description
    Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults
    id
    OG000
    title
    RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants
param Type
NUMBER
population Description
all patients who received the selectively depleted transplant including one special exemption
reporting Status
POSTED
time Frame
Dec 2011.
title
Overall Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice